Predicting the Response of Patients With Rheumatoid Arthritis to Treatment With Genetically Engineered Biological Drugs and Janus (JAK) Kinase Inhibitors

Conditions: Rheumatoid Arthritis Interventions: Drug: genetically engineered biological drugs, Janus-kinase inhibitors, tumor necrosis factor inhibitors Sponsors: Institute of Biomedical Chemistry, Russia; Moscow Regional Research and Clinical Institute Moniki n.a. M.F. Vladimirskiy Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials